IVX 0.00% 0.2¢ invion limited

Ann: INV103 ala-Cpn10 clinical trial in lupus complete, page-2

  1. 2,224 Posts.
    lightbulb Created with Sketch. 32
     Invion completes study of INV103 (ala-Cpn10) in patients with systemic lupus (SLE)
     Study designed to test safety and biochemical effect of materially higher doses than previous studies
     Data from patients’ cells show positive effect after one month of dosing
     Study supports larger, longer trials of Cpn10 in patients with autoimmune diseases
     Company to focus on partnering the drug asset

    Looks promising and good...
 
watchlist Created with Sketch. Add IVX (ASX) to my watchlist
(20min delay)
Last
0.2¢
Change
0.000(0.00%)
Mkt cap ! $13.33M
Open High Low Value Volume
0.2¢ 0.2¢ 0.2¢ $5K 2.5M

Buyers (Bids)

No. Vol. Price($)
51 44572040 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 6164641 17
View Market Depth
Last trade - 16.10pm 12/09/2024 (20 minute delay) ?
IVX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.